Works matching AU Sand, Michael


Results: 67
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Expression of PIWIL3 in primary and metastatic melanoma.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 3, p. 433, doi. 10.1007/s00432-016-2305-2
    By:
    • Gambichler, Thilo;
    • Kohsik, Christina;
    • Höh, Ann-Kathrin;
    • Lang, Kerstin;
    • Käfferlein, Heiko;
    • Brüning, Thomas;
    • Stockfleth, Eggert;
    • Stücker, Markus;
    • Dreißigacker, Max;
    • Sand, Michael
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Patched 1 expression in Merkel cell carcinoma.

    Published in:
    Journal of Dermatology (John Wiley & Sons, Inc.), 2021, v. 48, n. 1, p. 64, doi. 10.1111/1346-8138.15611
    By:
    • Gambichler, Thilo;
    • Dreißigacker, Max;
    • Kasakovski, Dimitri;
    • Skrygan, Marina;
    • Wieland, Ulrike;
    • Silling, Steffi;
    • Gravemeyer, Jan;
    • Melior, Anita;
    • Cherouny, Angela;
    • Stücker, Markus;
    • Stockfleth, Eggert;
    • Sand, Michael;
    • Becker, Jürgen C.
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Cutaneous lesions of the nose.

    Published in:
    Head & Face Medicine, 2010, v. 6, p. 7, doi. 10.1186/1746-160X-6-7
    By:
    • Sand, Michael;
    • Sand, Daniel;
    • Thrandorf, Christina;
    • Paech, Volker;
    • Altmeyer, Peter;
    • Bechara, Falk G.
    Publication type:
    Article
    41

    Cutaneous lesions of the external ear.

    Published in:
    Head & Face Medicine, 2008, v. 4, p. 1, doi. 10.1186/1746-160X-4-2
    By:
    • Sand, Michael;
    • Sand, Daniel;
    • Brors, Dominik;
    • Altmeyer, Peter;
    • Mann, Benno;
    • Bechara, Falk G.
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49

    Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

    Published in:
    Schizophrenia Bulletin, 2019, v. 45, n. 2, p. 350, doi. 10.1093/schbul/sby049
    By:
    • Brown, David;
    • Nakagome, Kazuyuki;
    • Cordes, Joachim;
    • Brenner, Ronald;
    • Gründer, Gerhard;
    • Keefe, Richard S E;
    • Riesenberg, Robert;
    • Walling, David P;
    • Daniels, Kristen;
    • Wang, Lara;
    • McGinniss, Jennifer;
    • Sand, Michael
    Publication type:
    Article
    50